Tests melatonin for nerve damage in people with type 2 diabetes
Tests melatonin added to usual care in adults with type 2 diabetes and nerve damage.
Plain-language title generated from the registry record
Registry title: Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07036796, who can take part
Where in Egypt
- Ain Shams University HospitalCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07036796
- Record updated
- 21 July 2026
- Original description
The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.Read full original descriptionShow less
Effect of Melatonin on the Clinical Outcomes in Type 2 Diabetic Patients With Peripheral Neuropathy
The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.
Inclusion: Patients aged 40-75 years diagnosed with type 2 DM; Diabetes duration at least 1 year; Patients diagnosed with diabetic peripheral neuropathy; Stable antidiabetic medication for at least 1 month before enrollment and during the trial.
Exclusion: Use of medications or supplements known to cause or treat peripheral neuropathy; Patients consuming any antioxidant supplements or anti-inflammatory medicines during or 3 months before enrollment; Patients with autoimmune disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients; Patients diagnosed with neurodegenerative diseases; Active infection; Allergy to melatonin; Patients with severe kidney or liver dysfunction; Alcohol consumption or substance abuse; Pregnancy or lactation or expecting to get pregnant during the study.